These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10184937)

  • 21. Prescription drug benefits: Rx for cost management--commentary.
    Carlsen MA
    Benefits Q; 1993; 9(3):81-8. PubMed ID: 10127207
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of pharmacoeconomic research for benefit design decision support.
    Navarro RP
    Med Interface; 1996 Apr; 9(4):78-80. PubMed ID: 10156025
    [No Abstract]   [Full Text] [Related]  

  • 23. How well does your PBM perform?
    McCarthy R
    Bus Health; 1999 Jan; 17(1):24-9. PubMed ID: 10345211
    [No Abstract]   [Full Text] [Related]  

  • 24. Managing prescription drug costs.
    Sica JM
    Empl Benefits J; 2001 Mar; 26(1):35-40. PubMed ID: 11272515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lowering of LDL cholesterol.
    Sniderman AD
    Lancet; 2000 Jan; 355(9199):235. PubMed ID: 10675147
    [No Abstract]   [Full Text] [Related]  

  • 26. Lipid-lowering interventions in managed care settings.
    Fox J; Jones K
    Am J Med; 2001 Apr; 110 Suppl 6A():24S-30S. PubMed ID: 11311194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Control of prescription costs--is it possible?
    Renaud PN
    Empl Benefits J; 2002 Mar; 27(1):11-4. PubMed ID: 11859536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managed care outlook. Employers struggle to preserve pharmacy benefit.
    Manag Care; 2002 Jan; 11(1):56. PubMed ID: 11828877
    [No Abstract]   [Full Text] [Related]  

  • 29. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.
    Goldman DP; Joyce GF; Karaca-Mandic P
    Am J Manag Care; 2006 Jan; 12(1):21-8. PubMed ID: 16402885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roundtable discussion. Achieving more aggressive low-density lipoprotein cholesterol lowering.
    Hunninghake DB; McKenney JM; Gotto AM; Mehta JL; Jones PH
    Am J Manag Care; 2000 Nov; 6(19 Suppl):S1008-16. PubMed ID: 11187369
    [No Abstract]   [Full Text] [Related]  

  • 31. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
    Davies GM; Vyas A; Baxter CA
    J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should health plans offer an OTC drug benefit?
    Navarro RP
    Med Interface; 1996 Jun; 9(6):100-1, 108. PubMed ID: 10157922
    [No Abstract]   [Full Text] [Related]  

  • 33. [Simvastatin 40 mg as secondary prophylaxis: Effective, tolerable and cost-efficient!].
    Hernborg A; Hjemdahl P; Håkansson J
    Lakartidningen; 2006 Mar 15-21; 103(11):858, 861; discussion 861-2. PubMed ID: 16613120
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful management of lipid-lowering programs.
    Wright AT
    Manag Care; 2001 Nov; 10(11 Suppl):10-3; discussion 19-24. PubMed ID: 11761624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balancing quality employee benefits with cost sharing.
    Lenda WM
    Am J Manag Care; 2006 Apr; 12(6 Suppl):S165-6; discussion S167-72; quiz S173-6. PubMed ID: 16613532
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of randomized controlled trials in organizational decision making: a cost-minimization approach.
    Cher DJ; Maclure M
    Am J Manag Care; 2000 Aug; 6(8):894-904. PubMed ID: 11186501
    [No Abstract]   [Full Text] [Related]  

  • 37. The Pharmaceutical Management Panel - highlights of the pharmacy business.
    Kirshenbaum D
    Dis Manag; 2003; 6(Suppl 1):S15-7. PubMed ID: 14751024
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [LDL cholesterol in cardiovascular risk patients should be as low as possible].
    MMW Fortschr Med; 2007 Oct; 149(41):44-5. PubMed ID: 17992793
    [No Abstract]   [Full Text] [Related]  

  • 40. New standard for pharmacy benefits.
    Walgran CC
    J Health Care Benefits; 1994; 3(3):60-4. PubMed ID: 10131221
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.